Xilio Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-12. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
The Board accepted such resignation and immediately re-appointed him as a Class III director.
Reported
Dr. Blanchard succeeds Christina Rossi, who notified the Company of her decision to resign from the Board and all committees thereof on April 15, 2026, effective as of such date.
Find people with the same kind of experience as the senior executive at Xilio Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Xilio Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Xilio Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Xilio Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Xilio Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.